• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial.

作者信息

Hart C, Vogelhuber M, Hafner C, Landthaler M, Berneburg M, Haferkamp S, Herr W, Reichle A

机构信息

Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.

Department of Dermatology, University Hospital of Regensburg, Regensburg, Germany.

出版信息

J Eur Acad Dermatol Venereol. 2016 Nov;30(11):e119-e121. doi: 10.1111/jdv.13391. Epub 2015 Sep 29.

DOI:10.1111/jdv.13391
PMID:26417987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5108438/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5a/5108438/4873e8d63a85/JDV-30-e119-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5a/5108438/4873e8d63a85/JDV-30-e119-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d5a/5108438/4873e8d63a85/JDV-30-e119-g001.jpg

相似文献

1
Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial.一项I期试验表明，IV期黑色素瘤的生物调节性节拍疗法耐受性良好，可能会延长无进展生存期。
J Eur Acad Dermatol Venereol. 2016 Nov;30(11):e119-e121. doi: 10.1111/jdv.13391. Epub 2015 Sep 29.
2
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.一项关于他西尤单抗钠与紫杉醇作为转移性黑色素瘤患者二线治疗的随机、开放标签临床试验。
Cancer. 2014 Jul 1;120(13):2016-24. doi: 10.1002/cncr.28635. Epub 2014 Mar 26.
3
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.来那度胺治疗转移性恶性黑色素瘤的多中心、随机、双盲、剂量评估2/3期研究结果
Cancer. 2009 Nov 15;115(22):5228-36. doi: 10.1002/cncr.24576.
4
A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).BRAF 突变型黑色素瘤 IV 期患者接受 MEK1/2 抑制剂 selumetinib（AZD6244）治疗后出现持久完全缓解。
Anticancer Drugs. 2012 Aug;23(7):761-4. doi: 10.1097/CAD.0b013e328350737d.
5
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.高危黑色素瘤的辅助性干扰素治疗：AIM HIGH研究——英国癌症研究协调委员会关于高危切除恶性黑色素瘤辅助低剂量延长疗程干扰素α-2a的随机研究
J Clin Oncol. 2004 Jan 1;22(1):53-61. doi: 10.1200/JCO.2004.03.185. Epub 2003 Dec 9.
6
Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.伊马替尼与贝伐单抗用于晚期黑色素瘤及其他晚期癌症患者的I/II期试验
Oncologist. 2015 Aug;20(8):952-9. doi: 10.1634/theoncologist.2015-0108. Epub 2015 Jun 17.
7
Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma.三氧化二砷用于晚期转移性黑色素瘤患者的安全性和有效性。
Cancer. 2008 Mar 1;112(5):1131-8. doi: 10.1002/cncr.23284.
8
Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.使用间歇性低剂量给药的吡曲克辛治疗转移性黑色素瘤的II期试验。
J Clin Oncol. 1991 Mar;9(3):464-7. doi: 10.1200/JCO.1991.9.3.464.
9
Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.大剂量干扰素α-2b方案用于切除高危黑色素瘤的疗程
J Clin Oncol. 2009 Sep 1;27(25):e82-3; author reply e84. doi: 10.1200/JCO.2009.23.0334. Epub 2009 Jul 27.
10
Vemurafenib: a guide to its use in unresectable or metastatic melanoma.维莫非尼：在不可切除或转移性黑色素瘤中的应用指南。
Am J Clin Dermatol. 2013 Feb;14(1):65-9. doi: 10.1007/s40257-012-0007-3.

引用本文的文献

1
Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity.过氧化物酶体增殖物激活受体α/γ激动剂吡格列酮通过开启表型可塑性来挽救复发或难治性肿瘤。
Front Oncol. 2024 Jan 11;13:1289222. doi: 10.3389/fonc.2023.1289222. eCollection 2023.
2
Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance.应对遗传性肿瘤异质性、治疗后转移扩散、癌症再增殖以及获得性肿瘤细胞耐药性的发展。
Cancers (Basel). 2023 Dec 29;16(1):180. doi: 10.3390/cancers16010180.
3
PPARs and the Kynurenine Pathway in Melanoma-Potential Biological Interactions.

本文引用的文献

1
Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia.适应性改变：肿瘤系统的交流重编程——用于从化疗难治性肿瘤中挽救生命
Cancer Microenviron. 2015 Aug;8(2):75-92. doi: 10.1007/s12307-015-0170-1. Epub 2015 Aug 11.
2
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
3
Biology of advanced uveal melanoma and next steps for clinical therapeutics.
过氧化物酶体增殖物激活受体与黑色素瘤中的犬尿氨酸途径：潜在的生物学相互作用。
Int J Mol Sci. 2023 Feb 4;24(4):3114. doi: 10.3390/ijms24043114.
4
Drug Repurposing by Tumor Tissue Editing.通过肿瘤组织编辑实现药物重新利用。
Front Oncol. 2022 Jun 24;12:900985. doi: 10.3389/fonc.2022.900985. eCollection 2022.
5
PPAR-Responsive Elements Enriched with Alu Repeats May Contribute to Distinctive PPARγ-DNMT1 Interactions in the Genome.富含Alu重复序列的过氧化物酶体增殖物激活受体反应元件可能有助于基因组中独特的过氧化物酶体增殖物激活受体γ- DNA甲基转移酶1相互作用。
Cancers (Basel). 2021 Aug 7;13(16):3993. doi: 10.3390/cancers13163993.
6
Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction.组织内环境稳定修复：纠正癌组织异常内环境稳定——超越诱导凋亡
Front Oncol. 2019 Dec 20;9:1408. doi: 10.3389/fonc.2019.01408. eCollection 2019.
7
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.PPAR 调节剂在健康与疾病中的探索与开发：临床证据的更新。
Int J Mol Sci. 2019 Oct 11;20(20):5055. doi: 10.3390/ijms20205055.
8
Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis.一种新型治疗原则——组织营养缺失的临床疗效
Front Pharmacol. 2018 Nov 28;9:1357. doi: 10.3389/fphar.2018.01357. eCollection 2018.
9
Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction.降低依托泊苷剂量可通过DNA损伤反应使细胞死亡方式从半胱天冬酶依赖性转变为分化及半胱天冬酶-3非依赖性凋亡，从而导致急性髓系白血病培养物灭绝。
Front Pharmacol. 2018 Nov 13;9:1307. doi: 10.3389/fphar.2018.01307. eCollection 2018.
10
Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML.在一例罕见的治疗相关高危骨髓增生异常综合征/急性髓系白血病中，生物调节疗法成功治疗皮肤白血病浸润
Front Pharmacol. 2018 Nov 13;9:1279. doi: 10.3389/fphar.2018.01279. eCollection 2018.
晚期葡萄膜黑色素瘤生物学及临床治疗的下一步措施
Pigment Cell Melanoma Res. 2015 Mar;28(2):135-47. doi: 10.1111/pcmr.12304. Epub 2014 Sep 1.
4
M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles.肿瘤相关巨噬细胞的 M2/M1 比值与具有 1 类和 2 类分子特征的葡萄膜黑色素瘤中 PPAR-γ 的表达。
Exp Eye Res. 2013 Feb;107:52-8. doi: 10.1016/j.exer.2012.11.012. Epub 2012 Nov 30.
5
Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.蛋白质组分析鉴定出 PPARγ 配体 15d-PGJ2 是一种新型的药物抑制黑色素瘤进展并干扰肿瘤-基质相互作用。
PLoS One. 2012;7(9):e46103. doi: 10.1371/journal.pone.0046103. Epub 2012 Sep 25.
6
Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma.环氧化酶 2（COX2）和过氧化物酶体增殖物激活受体γ（PPARG）是恶性黑色素瘤的阶段依赖性预后标志物。
PPAR Res. 2009;2009:848645. doi: 10.1155/2010/848645. Epub 2009 Jul 20.
7
Peroxisome proliferator-activating receptors: a new way to treat melanoma?过氧化物酶体增殖物激活受体：治疗黑色素瘤的新途径？
J Invest Dermatol. 2009 May;129(5):1061-3. doi: 10.1038/jid.2009.56.
8
Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial.晚期黑色素瘤的靶向联合抗炎和血管生成抑制治疗：一项随机II期试验
Melanoma Res. 2007 Dec;17(6):360-4. doi: 10.1097/CMR.0b013e3282f1d2c8.
9
Deregulated Akt3 activity promotes development of malignant melanoma.Akt3活性失调促进恶性黑色素瘤的发展。
Cancer Res. 2004 Oct 1;64(19):7002-10. doi: 10.1158/0008-5472.CAN-04-1399.